Memo Therapeutics AG’s Potravitug Granted Orphan Designation in the European Union

– Orphan designation confers market exclusivity, regulatory and financial benefits for medicines intended to treat rare diseases– Recognizes both medical plausibility of the initial clinical data and that potravitug targets a life-threatening or chronically debilitating condition, BKPyV infection, which affects fewer than 5 in 10,000 people Schlieren / Zurich, Switzerland, 18 December, 2025 – Memo […] The post Memo Therapeutics AG’s Potravitug Granted Orphan Designation in the European Union first appeared on Memo Therapeutics .